← Human Trials & Peer-Reviewed Studies
The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial
Plain-language guide to PMID 35576873 (2022): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84), low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 35576873
- Journal
- Nutrition (Burbank, Los Angeles County, Calif.)
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Cheung MM et al. (8 authors)
- DOI
- 10.1016/j.nut.2022.111674
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.
Magnesium is a cofactor that assists vitamin D metabolism.
Who Took Part
A total of 95 Owt/Ob participants were randomized into one of these three study arms.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.
Anthropometry, dietary intake, concentrations of serum 25OHD, serum parathyroid hormone (PTH), serum inflammatory markers, and blood pressure were obtained at baseline and week 12.
What Was Measured
PubMed files the paper under topics including Biomarkers, Blood Pressure, Cholecalciferol, Dietary Supplements, Inflammation, Magnesium and Obesity.
Author keywords: Cardiovascular health, Parathyroid hormone, Systemic inflammation and Vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in people with low blood pressure and orthostatic hypotension.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Nutrition (Burbank, Los Angeles County, Calif.)), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Low blood pressure and orthostatic hypotension research
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.